Intravitreal bevacizumab in a patient with a macular star in malignant hypertension

Ilaria Zucchiatti, Pierluigi Iacono, Maurizio Battaglia Parodi, Maria Lucia Cascavilla, Dimitris Stelios Kontadakis, Francesco Bandello

Research output: Contribution to journalArticlepeer-review


Purpose. To report a case of retinopathy secondary to malignant hypertension showing a macular star, which responded favorably to a single intravitreal injection of bevacizumab (IVB). Methods. A 46-year-old man with malignant hypertension showing incomplete macular star in his right eye with best-corrected visual acuity (BCVA) of 20/32 underwent IVB. Results. Subsequent examinations revealed a progressive resolution of the macular star with functional recovery over the follow-up. In particular, at the 9-month examination BCVA was 20/20, fundus bio-microscopy disclosed resolution of the macular star, and the retinal sensitivity improved remarkably. Conclusions. Intravitreal injection of bevacizumab can be a useful approach to treat the exudative manifestations of malignant hypertension.

Original languageEnglish
Pages (from-to)336-339
Number of pages4
JournalEuropean Journal of Ophthalmology
Issue number3
Publication statusPublished - May 2011


  • Intravitreal bevacizumab
  • Malignant hypertension
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Intravitreal bevacizumab in a patient with a macular star in malignant hypertension'. Together they form a unique fingerprint.

Cite this